

Annual intramuscular injection of a megadose of cholecalciferol for treatment of vitamin D deficiency: efficacy and safety data

Terrence H Diamond, Kenneth W Ho, Peter G Rohl and Matthew Meerkin

Vitamin D deficiency leads to hypocalcaemia, secondary hyperparathyroidism and increased bone turnover.^{1,2} This may be associated with osteoporosis and fractures.¹ In prolonged and severe cases, osteomalacia and rickets (failure in mineralisation of new bone) may occur, resulting in progressive bone pains, myopathy and a waddling gait.³ Vitamin D deficiency is not uncommon in “sunny” Australia.⁴ The clinical spectrum ranges from subclinical to frank deficiency, with serum 25-hydroxyvitamin D (25OHD) levels less than 20 nmol/L. The prevalence of vitamin D deficiency among elderly people living in residential homes has been estimated to be at least 50%.⁵ Severe deficiency was also reported in 80% of “veiled” pregnant women.⁶ Other high-risk groups include ethnic populations from the Horn of Africa, India and Pakistan, and patients with gastrointestinal malabsorption syndromes.^{4,7} Vitamin D repletion can improve bone mineral density and reduce fracture risk.⁸ The usual method of supplementation with oral ergocalciferol tablets (1000 IU) is often inadequate, especially in severe deficiency states.^{4,9} In Australia, there are currently no effective high-dose vitamin D preparations.

METHODS

We conducted a prospective open-label study in a single institution to assess the safety and efficacy of a single therapeutic annual intramuscular injection of 600 000 IU (15 mg) cholecalciferol (vitamin D₃; “Arachitol”, Solvay Pharma, India Ltd) in treating vitamin D deficiency. This preparation is currently being used to treat vitamin D deficiency in India and Canada,¹⁰ and its safety has previously been evaluated.⁹

Men and women with biochemical evidence of vitamin D deficiency (serum 25-hydroxyvitamin D₃ [25OHD₃], <50 nmol/L) were

FOR EDITORIAL COMMENT, SEE PAGE 4

St George Hospital, Sydney, NSW.

Terrence H Diamond, MBChB, MRCP, FRACP, Endocrinologist; Kenneth W Ho, MBBS, Endocrinology Registrar; Peter G Rohl, MBBS, FRACP, Endocrinologist.

MayneHealth Laverty Pathology, Sydney, NSW.

Matthew Meerkin, FRCPA, FAACB, FACB, Chemical Pathologist.

Reprints will not be available from the authors. Correspondence: Associate Professor Terrence H Diamond, St George Hospital, University of New South Wales, Pritchard Wing Level 3, Gray Sreet, Kogarah, NSW 2217. terrydiamond@optushome.com.au

ABSTRACT

Aim: To evaluate the efficacy and safety of an annual intramuscular injection of cholecalciferol for vitamin D deficiency.

Design: Prospective open-label study.

Participants: Five men and 45 women (mean age 66.3 years) with vitamin D deficiency who were given a single therapeutic intramuscular injection of 600 000 IU (15 mg) cholecalciferol (vitamin D₃).

Outcome measures: Serum levels of calcium, creatinine, 25-hydroxyvitamin D₃ (25OHD₃) and parathyroid hormone, as well as early morning 2-hour urine calcium/creatinine excretion index. Specimens were collected at baseline and after 4 and 12 months of therapy. Data are reported as mean ± 1 SD.

Results: Vitamin D deficiency was severe (< 12.5 nmol/L) in one participant, moderate (12.5–24 nmol/L) in 14, and mild (25–49 nmol/L) in 35. Twenty-four participants (48%) had secondary hyperparathyroidism. Following intramuscular cholecalciferol injection, serum 25OHD₃ levels normalised in all participants and remained above 50 nmol/L throughout the study. Serum 25OHD₃ levels were significantly higher at 4 months (114 ± 35 nmol/L), and 12 months (73 ± 13 nmol/L) compared with baseline (32 ± 8 nmol/L) (*P* < 0.001), increasing by an average of 128% over the 12 months. There was a corresponding decrease in serum parathyroid hormone levels at 4 months (6 ± 3 pmol/L) and at 12 months (5.2 ± 3 pmol/L), with a 30% decrease at 12 months from baseline (7.4 ± 4 pmol/L) (*P* < 0.01). Primary hyperparathyroidism was unmasked in one participant at 4 months and mild hypercalcaemia (serum calcium, < 2.70 mmol/L) was noted in two participants (4%) at 12 months. Serum creatinine levels remained normal in all participants throughout the study, while increases in 2-hour urine calcium/creatinine excretion index were seen in 10 participants (20%) at 12 months, three of whom had elevated values at baseline.

Conclusions: Once-yearly intramuscular cholecalciferol injection (600 000 IU) is effective therapy for vitamin D deficiency. While this therapy appears to be safe, the potential for developing hypercalciuria needs to be examined in a large randomised controlled trial.

MJA 2005; 183: 10–12

recruited from the metabolic bone clinic at St George Hospital. All gave informed consent, and treatment was administered on an Individual Patient Use (IPU) special access scheme according to Therapeutic Goods Administration of Australia guidelines. Patients were excluded if they had hypercalcaemia (serum calcium, > 2.65 mmol/L), primary hyperparathyroidism (hypercalcaemia with inappropriately elevated serum parathyroid hormone levels), thyrotoxicosis, Paget’s disease, malignancy, significant renal impairment (serum

creatinine, > 0.15 mmol/L), significantly elevated early-morning 2-hour urine calcium/creatinine excretion index (> 0.8), liver disease (alanine aminotransferase or aspartate aminotransferase level > 2 times the upper limit of the normal range), or current treatment with calcitriol or high-dose oral calcium supplements (1200 mg/day of elemental calcium).

Participants were evaluated by biochemical assessments at baseline and after 4 and 12 months of therapy. The study was performed according to National Health and Medical Research Council guidelines and with approval of the South Eastern Area Health Service Research Ethics Committee.

Serum (fasting) and urinary (2 hour) calcium, urea and creatinine levels were determined by autoanalyser methods. Hypercalcaemia was defined as a serum calcium concentration higher than 2.65 mmol/L. Two-hour urine calcium/creatinine excretion

Serum and urine biochemical findings in 50 patients with vitamin D deficiency at baseline and after 4 and 12 months of therapy, and the serum 25-hydroxyvitamin D₃ reponse over that period

Variable	Reference range	Baseline	4 months	12 months	Change (baseline to 12 months)
Serum					
Calcium*	2.2–2.65 mmol/L	2.40±0.11	2.40±0.12	2.45±0.10	+2%
25-hydroxyvitamin D ₃ *	> 50 nmol/L	32±8.4	114±35 [§]	73±13 [§]	+128%
Creatinine [†]	< 0.11 mmol/L	0.08±0.02	0.07±0.02	0.08±0.03	0
Parathyroid hormone [†]	< 7.5 pmol/L	7.4±4	6±3	5.2±3*	-30%
Urine					
2-hour urine calcium/creatinine excretion index [†]	< 0.6	0.25±0.2	0.29±0.3	0.40±0.3 [†]	+60%

Values expressed as mean ±1 SD. *Comparison by analysis of variance and post hoc Scheffe test. † Comparison with Kruskal–Wallis test. ‡ P < 0.01 and § P < 0.001 (compared with baseline).

indices were used to determine hypercalcaemia. This was based on a previous study,¹¹ and validated in our laboratory. A urine calcium/creatinine excretion index over 0.60 was considered abnormal.

Serum 25OHD₃ levels were measured by radioimmunoassay (Immuno Diagnostic Systems, Boldon, UK). Specificity for 25OHD₃ was 100%, and intra-assay precision was 5.3% at 26.5 nmol/L and 6.1% at 151 nmol/L.

Serum levels of intact parathyroid hormone (PTH) were measured by chemiluminometric technology (Advia Centaur Assay, Bayer Corp, USA). The intra-assay precision was 5.2% at 4.3 pmol/L and 3.4% at 23.7 pmol/L. Hyperparathyroidism was defined as a serum PTH level over 7.5 pmol/L.

Statistical analysis

Data are presented as mean ±1 SD. Group mean values were compared by analysis of variance with a post hoc Scheffe test for parametric data and Kruskal–Wallis test for non-parametric data. Logarithmic regression analysis was used to determine the relationship between serum PTH and 25OHD₃ levels.

RESULTS

There were 5 men and 45 women with evidence of vitamin D deficiency and who fulfilled the inclusion criteria. They were aged 32–87 years (mean age, 66.3 years). They had been referred for management of osteoporosis (37) and musculoskeletal pains (13). Thirteen participants were receiving low dose glucocorticoids for rheumatological conditions, two had previously undergone gastrectomy and one had biopsy-proven coeliac disease. No patient declined intramuscular cholecalciferol therapy and none reported any serious adverse events. One patient developed a localised ery-

thematous reaction at the injection site, which resolved after 2 weeks of applying a topical glucocorticoid preparation. There were no reports of bruising or bleeding at the injection site.

Vitamin D deficiency among the 50 participants was classified as mild (25–49 nmol/L) in 35 (70%), moderate (12.5–24 nmol/L) in 14 (28%), and severe (< 12.5 nmol/L) in 1 (2%).⁹ Treatment with intramuscular cholecalciferol normalised serum 25OHD₃ levels in all patients, with levels remaining above 50 nmol/L after 12 months of therapy (Box). Twenty-four participants (48%) had secondary hyperparathyroidism. Intramuscular cholecalciferol injection normalised serum PTH levels in 16 participants (67%). The mean serum PTH level decreased by 30%, from a baseline value of 7.4±4.4 pmol/L to a 12-month value of 5.2±3.2 pmol/L (Box). There was an inverse relationship between baseline serum 25OHD₃ and PTH levels ($y = 18.5 - 3.25[\log x]$; $r = 0.21$; $P = 0.02$).

Primary hyperparathyroidism was unmasked after intramuscular cholecalciferol injection in one participant who subsequently underwent parathyroid adenectomy. This patient's serum calcium level increased from 2.64 mmol/L to 2.78 mmol/L at 4 months, and was associated with an elevated serum PTH level of 7.7 pmol/L. Two participants (4%) were noted to have mild hypercalcaemia at 12 months. Their serum calcium levels measured 2.66 mmol/L and 2.68 mmol/L, respectively, and PTH levels were 0.7 pmol/L and 2.2 pmol/L, respectively. Serum calcium levels in the rest of the cohort were normal at 4 and 12 months after therapy.

Serum creatinine levels remained within the normal range and unchanged throughout the study in all participants, but a small progressive increase in urine calcium/creatinine ex-

cretion index of 0.15 was noted with time (Box). The urine calcium/creatinine excretion index in four participants was 0.60–0.80, and in six it was > 0.80 at 12 months; in three of these, the urine calcium/creatinine excretion index was elevated at baseline.

DISCUSSION

Vitamin D repletion in individuals presenting with vitamin D deficiency has been shown to have a positive effect on bone biology, resulting in mineralisation of osteoid, increases in bone mineral density measurements and reduced fracture rates. A report of bone histomorphometric changes in 28 patients with osteomalacia treated with various vitamin D preparations and calcium showed an 80% reduction in osteoid volume and an increase in mineralised bone volume in cortical (+7.5%) and trabecular bone (+40%) after therapy.¹² Moreover, in a recent meta-analysis, there were significant increases in lumbar spine bone mineral density after only 12 months of therapy, while increases in femoral neck bone mineral density were much slower.¹³ In a landmark trial in elderly institutionalised women, 800 IU of oral vitamin D₃ with calcium supplements resulted in significant reduction in both non-vertebral (3.8%) and hip (2%) fractures, and a significant improvement in femoral neck bone density after 36 months of therapy.⁸ In another randomised controlled trial involving 2686 men and women aged over 65, 100 000 IU of oral vitamin D₃ given every 4 months reduced major osteoporotic fractures by 33% compared with placebo over 5 years.¹⁴ There are also data to suggest that an annual intramuscular injection of 150 000–300 000 IU of ergocalciferol (vitamin D₂)

has been associated with a reduction in fractures of the upper limbs.¹⁵

The major source of vitamin D in humans is sunlight. In the absence of adequate sunlight exposure, supplementation becomes important. The target for vitamin D supplementation is suggested to be a serum level of 50 nmol/L, which is protective against secondary hyperparathyroidism and decreased bone density.¹⁶ In Australia, the National Health and Medical Research Council recommends a daily oral intake of at least 400 IU vitamin D for those who are at risk of vitamin D deficiency.¹⁷ However, for those with severe vitamin D deficiency, higher doses are recommended.⁴

The main vitamin D supplements available in Australia are oral vitamin D₂ and D₃ preparations. The largest single dose is Ostelin (Boots Healthcare Australia), a 1000 IU D₂ preparation. Other vitamin D₂ preparations have lower doses (about 400 IU), and are usually combined with elemental calcium. A popular vitamin D₃ preparation is Caltrate 600 MG + Vitamin D Tablets (Wyeth Consumer Healthcare), which contain 200 IU of vitamin D₃ combined with 600 mg of elemental calcium. Other D₃ preparations include Pluravit (400 IU; Bayer Australia) and Elevit (500 IU; Roche Products). Currently there are no parenteral or oral megadoses of vitamin D₂ or D₃ preparations available in Australia.

Doses of 400–800 IU are safe and reportedly have no side effects.^{9,18} Such formulations can be purchased by anyone over the counter without the need for signed prescription. However, vitamin D preparations with doses above 1000 IU are considered as pharmaceutical agents, and are regulated by a much stricter code by the Australian Therapeutic Goods and Drug Administration Committee. Higher doses of 100 000–300 000 IU have been administered orally or intramuscularly 6-monthly or once-yearly quite safely without causing hypercalcaemia or renal impairment.^{9,19,21} Also, in one study, graded oral dosing of vitamin D₃ up to 50 000 IU daily for 8 weeks did not cause hypercalcaemia.²² In another, 50 000 IU of oral vitamin D₂ was administered twice-weekly to 12 patients with vitamin D deficiency (serum 25OHD, <35 nmol/L) for 5 weeks (total dose, 500 000 IU).²³ These patients also received 1000 mg of calcium orally. At 10 months, their serum 25OHD level had increased significantly by 145% (P<0.001), with the urine calcium/creatinine excretion index increasing by 20% above baseline (P<0.01) but still remaining within the normal range. Importantly, the serum calcium level did not change significantly. Similarly, a report from New

Zealand described supplementation with 500 000 IU in a 10-day course of 50 000 IU of oral cholecalciferol.²⁴ Participants' mean serum calcium level increased by 0.06 ± 0.08 mmol/L (P<0.001) after treatment, but in none did the calcium level exceed the reference range after treatment.

In our study, a single annual intramuscular injection of 600 000 IU cholecalciferol was administered to 50 vitamin D-deficient participants. The therapy was effective, with normalisation of serum 25OHD levels and maintenance of a level well above 50 nmol/L at 12 months. This result was achieved with very little change in serum calcium levels and no deterioration in renal function, although there was a progressive increase in urine calcium excretion indices. The latter usually suggests an obligatory calcium loss, and may have been affected by oral calcium intakes. These findings raise the possibility of hypercalcaemia. Future randomised controlled trials which include 24-hour urine calcium excretion measurements will be essential for validating the safety of megadose intramuscular cholecalciferol therapy.

We suggest that a once-yearly intramuscular cholecalciferol injection (600 000 IU) should be further investigated as a therapeutic option for treating vitamin D deficiency. This treatment is currently unavailable in Australia, and there is no ideal preparation of megadose vitamin D₂ or D₃ to fill this therapeutic gap. However, at a cost of \$5–\$10 per injection annually compared with \$35 for a monthly course of 5 Ostelin capsules daily (suggested dosages to treat vitamin D deficiency),⁴ it is remarkably cost-effective. The simple dosing regimen also allows convenient outpatient management and may improve patient compliance.

ACKNOWLEDGEMENTS

We thank Dr Anthony O'Sullivan for his editorial input and helpful suggestions.

COMPETING INTERESTS

None identified.

REFERENCES

- Leboff MS, Kohlmeier L, Hurwitz S, et al. Occult vitamin D deficiency in postmenopausal US women with acute hip fractures. *JAMA* 1999; 281: 1505-1511.
- Adams JS, Kantorovich V, Wu C, et al. Resolution of vitamin D insufficiency in osteopenic patients results in rapid recovery of bone mineral density. *J Clin Endocrinol Metab* 1999; 84: 2729-2730.
- Preece MA, McIntosh WB, Tomlinson S, et al. Vitamin D deficiency among Asian immigrants to Britain. *Lancet* 1973; 1: 907-910.
- Diamond TH, Eisman JA, Mason RS, et al. Vitamin D and adult bone health in Australia and New Zealand: a position statement. *Med J Aust* 2005; 182: 281-285.

- Flicker L, Mead K, MacInnis RJ, et al. Serum vitamin D and falls in older women in residential care in Australia. *J Am Geriatr Soc* 2003; 51: 1533-1538.
- Grover S, Morley R. Vitamin D deficiency in veiled or dark-skinned pregnant women. *Med J Aust* 2001; 175: 251-252.
- Skull SA, Ngeow JYY, Biggs BA, et al. Vitamin D deficiency is common and unrecognised among recently arrived adult immigrants from The Horn of Africa. *Int Med J* 2003; 33: 47-51.
- Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D₃ and calcium to prevent hip fractures in elderly women. *N Engl J Med* 1992; 327: 1637-1642.
- Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. *Am J Clin Nutr* 1999; 69: 842-856.
- MedIndia Drug Directory. Available at: http://www.medindia.net/doctors/drug_directory.asp (accessed May 2005).
- So NP, Osorio AV, Simon SD, Alon US. Normal urinary calcium/creatinine ratios in African-American and caucasian children. *Pediatr Nephrol* 2001; 16: 133-139.
- Parfitt AM, Rao DS, Stanciu J, et al. Irreversible bone loss in osteomalacia: comparison of radial photon absorptiometry with iliac bone histomorphometry during treatment. *J Clin Invest* 1985; 76: 2403-2412.
- Papadimitropoulos E, Wells G, Shea B, et al. Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. *Endocr Rev* 2002; 23: 560-569.
- Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D₃ (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised controlled trial. *BMJ* 2003; 326: 469-474.
- Heikinheimo RJ, Inkovaara JA, Harju EJ, et al. Annual injection of vitamin D and fractures of aged bones. *Calcif Tissue Int* 1992; 51: 105-110.
- Peacock M, Selby PL, Francis RM, et al. Vitamin D deficiency, insufficiency, sufficiency, and intoxication, what do they mean? In: Schaefer NA, Grigolletti MG, Herrath DV, editors. Sixth workshop on vitamin D. Berlin: DeGruyter, 1985: 569-570.
- National Health and Medical Research Council. Recommended dietary intakes for use in Australia. Canberra: AGPS, 1991.
- Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. *Endocr Rev* 2001; 22: 477-501.
- Khaw KT, Scragg R, Murphy S. Single-dose cholecalciferol suppresses the winter increase in parathyroid hormone concentrations in healthy older men and women. *Am J Clin Nutr* 1994; 59: 1040-1044.
- Davies M, Mawer EB, Hann JT, et al. Vitamin D prophylaxis in the elderly: a simple, effective method suitable for large populations. *Age Ageing* 1985; 14: 349-352.
- Weisman Y, Schen RJ, Eisenberg Z, et al. Single oral high-dose vitamin D₃ prophylaxis in the elderly. *J Am Geriatr Soc* 1986; 34: 515-518.
- Barger-Lux MJ, Heaney RP, Dowell S, et al. Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men. *Osteoporos Int* 1998; 8: 222-230.
- Adams JS, Kantorovich V, Wu C, et al. Resolution of vitamin D insufficiency in osteopenic patients results in rapid recovery of bone mineral density. *J Clin Endocrinol Metab* 1999; 84: 2729-2730.
- Wu F, Staykova T, Home A, et al. Efficacy of an oral, 10-day course of high-dose calciferol in correcting vitamin D deficiency. *N Z J Med* 2003; 116: 536-539.

(Received 25 Jan 2005, accepted 4 Apr 2005) □

Megadose therapy for vitamin D deficiency

Treating the paradox of an important emerging public health problem

The international perception of bronzed Australians inhabiting a “sunburnt country” is under threat. Most Australians, including children, now sensibly avoid excessive sun exposure to reduce the risk of skin cancer. However, other Australians, particularly those who are older, disabled or institutionalised often do not receive even modest levels of sunlight exposure. This has led to the paradox of vitamin D deficiency emerging as a public health issue in sunny Australia.

Besides older and institutionalised Australians, others particularly at risk of vitamin D deficiency are people with pigmented skin from Africa, India and Pakistan; women who practise veiling; those on certain medications (eg, anti-epileptic drugs); and those with malabsorption or a low vitamin D intake. Even young Australians, pregnant women and their infants are at risk of this emerging health problem.¹ The prevalence of vitamin D deficiency among Indigenous Australians has not been determined, but is likely to be high.

The problem was highlighted recently in the Journal in a position statement on vitamin D and bone health in adults.²

Vitamin D deficiency is usually classified as mild (25-hydroxyvitamin D [25OHD] level, 25–49 nmol/L), moderate (12.5–24 nmol/L) or severe (<12.5 nmol/L). The Geelong Osteoporosis Study detected mild or moderate deficiency in more than one in three women surveyed in summer, which rose to one in two in winter.³ Even in south-east Queensland, Western Australia, New South Wales and Victoria, nearly a third of men and women have mild to moderate vitamin D deficiency.⁴ Almost half of nursing home patients, and almost all patients in aged care facilities surveyed have at least mild vitamin D deficiency.

Thus, despite Australia being a “sunburnt country”, vitamin D deficiency is common. But why is it important?

Severe vitamin D deficiency results in osteomalacia in adults and rickets in children. Milder vitamin D deficiency results in secondary hyperparathyroidism and increased bone turnover, predisposing to osteoporosis. Proximal myopathy and muscle pains may occur in moderate or severe vitamin D deficiency, and the incidence of falls is increased.⁵ Less well known is the impact of vitamin D deficiency on depression, immunity and autoimmunity, obesity, and the progression of type 2 diabetes mellitus.

It is also important to correct vitamin D deficiency to optimise the effects of other anti-osteoporotic drugs. In a recent United States study of 1536 women receiving anti-osteoporotic therapy, 52% had vitamin D deficiency.⁶ Treatment with intravenous or (more rarely) oral bisphosphonates may also cause severe hypocalcaemia in people with severe vitamin D deficiency,^{7,8} so it is prudent to screen for vitamin D deficiencies before initiating bisphosphonate therapy.

In the broad context of vitamin D deficiency as an emerging public health issue, the article by Diamond et al in this issue of the Journal (*page 10*)⁹ is timely. Their prospective open label study of 50 elderly women and men with vitamin D deficiency showed that a single intramuscular injection of 600 000 IU (or 15 mg) of cholecalciferol (vitamin D₃) increased serum 25OHD concentra-

tions to above 50 nmol/L in all patients. Over 12 months, serum 25OHD concentration rose, on average, by 128% to 73 nmol/L — a level most would consider to be optimal. Secondary hyperparathyroidism, present in about 50% of participants, was abolished in most. The complications of the therapy were mild hypercalcaemia in two participants (4%) and fasting hypercalciuria in 10 participants (20%) tested at 12 months.

The study by Diamond and colleagues represents a step forward in currently available treatment options for vitamin D deficiency. Currently, this is limited to doses of 200–1000 IU of either vitamin D₂ (ergocalciferol) or vitamin D₃ (cholecalciferol). The commonest form is 1000 IU of ergocalciferol (Ostelin; Boots Healthcare Australia). Loading doses of 3000–5000 IU per day are required to treat severe vitamin D deficiency and, as commercially available

radioimmunoassays do not always measure vitamin D₂ as well as vitamin D₃, measuring treatment response is difficult. Daily dosing is also difficult or unrealistic for many community-dwelling older people in whom compliance would be expected to be poor. A single

intramuscular “megadose” of cholecalciferol would overcome this compliance issue in a simple and cost-effective manner. The mild hypercalcaemia and fasting hypercalciuria are of concern, but further controlled trials are planned, which will include 24-hour urine calcium excretion measurements, to evaluate the safety of “megadose” cholecalciferol therapy. The effect of this treatment on fracture risk is not established. A recent British study of 9440 community-dwelling participants aged 75–100 years, randomly allocated to receive either an annual injection of 300 000 IU cholecalciferol or placebo, showed no reduction in fracture rate.¹⁰ Nevertheless, the greatest clinical utility of an annual megadose injection is likely to be in older institutionalised people, most of whom are vitamin D deficient.

The most important outcome in osteoporosis prevention or treatment is a reduction in fracture risk. Some data suggest treating vitamin D deficiency may prevent low-trauma fractures. A large French study in institutionalised, ambulatory older women found that daily doses of 800 IU of cholecalciferol and 1.2 g of calcium significantly decreased the incidence of hip and non-vertebral fractures compared with placebo after 18 months.¹¹ Daily vitamin D and calcium treatment also reduced non-vertebral fractures in community-dwelling older American men and women.¹² A recent large trial in community-dwelling British men and women aged over 65 years showed that a large oral dose of cholecalciferol (100 000 IU) every 4 months reduced osteoporotic fractures by 33%.¹³ The RECORD trial attempted to determine the relative contribution of calcium versus vitamin D on fractures. Ambulatory patients (5292) who had sustained a low-trauma fracture were randomly allocated to receive calcium (1000 mg/day), vitamin D₃ (800 IU/day), a combination of the two, or placebo. After at least 24 months, fracture rates did not differ between the four groups. However, compliance at 2 years was poor.¹⁴ Further large studies of vitamin D and its effects on fractures and falls are still needed, particularly in populations at risk of vitamin D deficiency; these

...despite Australia being a “sunburnt country”, vitamin D deficiency is common. But why is it important?

EDITORIALS

studies need to use varying oral doses of vitamin D and to include men.

The treatment described by Diamond et al is a good start to introducing new alternatives for treatment of vitamin D deficiency in targeted people. However, much more work is needed to identify successful public health approaches that can be more broadly applied to this emerging public health problem.

Peter R Ebeling

Deputy Director

Department of Diabetes and Endocrinology; and
Senior Principal Fellow and Associate Professor, Department of
Medicine, University of Melbourne, Royal Melbourne Hospital
Melbourne, VIC 3050

Peter.Ebeling@mh.org.au

- 1 Chatfield S, Ebeling PR. Osteoporosis prevention and treatment: the importance of vitamin D. *Mod Med* 2005; 6: 16-32.
- 2 Working Group of the Australian and New Zealand Bone and Mineral Society, Endocrine Society of Australia and Osteoporosis Australia. Vitamin D and adult bone health in Australia and New Zealand: a position statement. *Med J Aust* 2005; 182: 281-285.
- 3 Pasco JA, Henry MJ, Nicholson GC, et al. Vitamin D status of women in the Geelong Osteoporosis Study: association with diet and casual exposure to sunlight. *Med J Aust* 2001; 175: 401-405.
- 4 McGrath JJ, Kimlin MG, Saha S, et al. Vitamin D insufficiency in south-east Queensland. *Med J Aust* 2001; 174: 150-151.

- 5 Frame B, Parfitt AM. Osteomalacia: current concepts. *Ann Intern Med* 1978; 89: 966-982.
- 6 Holick MF, Siris ES, Binkley N, et al. Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. *J Clin Endocrinol Metab* 2005; 90: 3215-3224. Epub 2005 Mar 29.
- 7 Peter R, Mishra V, Fraser WD. Severe hypocalcaemia after being given intravenous bisphosphonate. *BMJ* 2004; 328: 335-336.
- 8 MacIsaac RJ, Seeman E, Jerums G. Seizures after alendronate. *J R Soc Med* 2002; 95: 615-616.
- 9 Diamond TH, Ho KWK, Rohl PG, Meerkin M. Annual intramuscular injection of a megadose of cholecalciferol for treatment of vitamin D deficiency: efficacy and safety. *Med J Aust* 2005; 183: 10-12.
- 10 Anderson FH, Smith HE, Raphael HM, et al. Effect of annual intramuscular vitamin D supplementation on fracture risk in 9440 community living older people: the Wessex Fracture Prevention Trial [abstract]. *J Bone Miner Res* 2004; 19(Suppl 1): Abstract no. 1220.
- 11 Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D₃ and calcium to prevent hip fractures in the elderly women. *N Engl J Med* 1992; 327: 1637-1642.
- 12 Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. *N Engl J Med* 1997; 337: 670-676.
- 13 Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D₃ (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: a randomised double blind controlled trial. *BMJ* 2003; 326: 469-475.
- 14 The RECORD Trial Group. Oral vitamin D₃ and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. *Lancet* 2005; 365: 1621-1628. □